Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [

CT perfusion Dynamic positron emission tomography (PET) Kinetic analysis Non-small cell lung cancer (NSCLC) Pathologic complete response (pCR) Stereotactic ablative radiation therapy (SABR) [18F]FDG

Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
13 Jan 2021
Historique:
received: 11 06 2020
accepted: 08 01 2021
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 22 9 2021
Statut: epublish

Résumé

Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult. This prospective study aimed to develop a predictive model for true pathologic complete response (pCR) to SABR using imaging-based biomarkers from dynamic [ Twenty-six patients with early-stage NSCLC treated with SABR followed by surgical resection were included, as a pre-specified secondary analysis of a larger study. Dynamic [ RPA identified three response groups based on tumour blood volume before SABR (BV In this study, we developed a predictive model based on dynamic [ MISSILE-NSCLC, NCT02136355 (ClinicalTrials.gov). Registered May 8, 2014, https://clinicaltrials.gov/ct2/show/NCT02136355.

Sections du résumé

BACKGROUND BACKGROUND
Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult. This prospective study aimed to develop a predictive model for true pathologic complete response (pCR) to SABR using imaging-based biomarkers from dynamic [
METHODS METHODS
Twenty-six patients with early-stage NSCLC treated with SABR followed by surgical resection were included, as a pre-specified secondary analysis of a larger study. Dynamic [
RESULTS RESULTS
RPA identified three response groups based on tumour blood volume before SABR (BV
CONCLUSIONS CONCLUSIONS
In this study, we developed a predictive model based on dynamic [
TRIAL REGISTRATION BACKGROUND
MISSILE-NSCLC, NCT02136355 (ClinicalTrials.gov). Registered May 8, 2014, https://clinicaltrials.gov/ct2/show/NCT02136355.

Identifiants

pubmed: 33441162
doi: 10.1186/s13014-021-01747-z
pii: 10.1186/s13014-021-01747-z
pmc: PMC7805034
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Banques de données

ClinicalTrials.gov
['NCT02136355']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11

Subventions

Organisme : Canada Foundation for Innovation
ID : 11358
Organisme : Ontario Institute for Cancer Research
ID : Clinician-Scientist Grant

Références

Cancer Treat Rev. 2008 Dec;34(8):719-27
pubmed: 18657910
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1057-65
pubmed: 17905527
J Nucl Med. 2012 Apr;53(4):521-9
pubmed: 22414637
BMC Cancer. 2012 Jul 23;12:305
pubmed: 22823994
Anticancer Res. 2001 Nov-Dec;21(6B):4285-300
pubmed: 11908683
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):974-8
pubmed: 20932655
Eur J Radiol. 2011 Jul;79(1):147-54
pubmed: 19954913
Lung Cancer. 2007 May;56(2):229-34
pubmed: 17353064
Breast Cancer Res Treat. 2009 Sep;117(2):325-31
pubmed: 19152025
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Psychol Methods. 2009 Dec;14(4):323-48
pubmed: 19968396
J Med Imaging Radiat Oncol. 2019 Feb;63(1):94-101
pubmed: 30281918
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92
pubmed: 18164849
JAMA Oncol. 2019 May 1;5(5):681-688
pubmed: 30789648

Auteurs

Dae-Myoung Yang (DM)

Department of Medical Biophysics, Schulich School of Medicine and Dentistry, University of Western Ontario, 1151 Richmond St N, London, ON, N6A 5C1, Canada.
Robarts Research Institute, University of Western Ontario, 1151 Richmond St N, London, ON, N6A 3K7, Canada.
Lawson Imaging Research Program, Lawson Health Research Institute, 268 Grosvenor St, London, ON, N6A 4V2, Canada.

David A Palma (DA)

Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.
Department of Radiation Oncology, London Regional Cancer Program, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Keith Kwan (K)

Pathology and Laboratory Medicine, London Health Sciences Centre, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Alexander V Louie (AV)

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada.

Richard Malthaner (R)

Department of Surgery, Division of Thoracic Surgery, London Health Sciences Centre, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Dalilah Fortin (D)

Department of Surgery, Division of Thoracic Surgery, London Health Sciences Centre, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

George B Rodrigues (GB)

Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.
Department of Radiation Oncology, London Regional Cancer Program, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Brian P Yaremko (BP)

Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.
Department of Radiation Oncology, London Regional Cancer Program, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Joanna Laba (J)

Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.
Department of Radiation Oncology, London Regional Cancer Program, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Stewart Gaede (S)

Department of Medical Biophysics, Schulich School of Medicine and Dentistry, University of Western Ontario, 1151 Richmond St N, London, ON, N6A 5C1, Canada.
Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.
Department of Radiation Oncology, London Regional Cancer Program, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Andrew Warner (A)

Department of Radiation Oncology, London Regional Cancer Program, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Richard Inculet (R)

Department of Surgery, Division of Thoracic Surgery, London Health Sciences Centre, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada.

Ting-Yim Lee (TY)

Department of Medical Biophysics, Schulich School of Medicine and Dentistry, University of Western Ontario, 1151 Richmond St N, London, ON, N6A 5C1, Canada. tlee@imaging.robarts.ca.
Robarts Research Institute, University of Western Ontario, 1151 Richmond St N, London, ON, N6A 3K7, Canada. tlee@imaging.robarts.ca.
Lawson Imaging Research Program, Lawson Health Research Institute, 268 Grosvenor St, London, ON, N6A 4V2, Canada. tlee@imaging.robarts.ca.
Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada. tlee@imaging.robarts.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH